Some great new SEPR patents:
WO00010572A1 03/02/2000 USE OF HYDROXYRISPERIDONE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND PREVENTION OF PSYCHOSES, EMESIS AND SYMPTOMS OF WITHDRAWAL FROM ALCOHOL AND NICOTINE
WO00010554A2 03/02/2000 METHODS AND COMPOSITIONS EMPLOYING OPTICALLY PURE S(+) VIGABATRIN
WO00010551A2 03/02/2000 METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS
WO00007976A1 02/17/2000 FLUOXETINE PROCESS FROM BENZOYLACETONITRILE
WO00006165A1 02/10/2000 METHODS AND COMPOSITIONS FOR TREATING GASTRO-ESOPHAGEAL REFLUX DISEASE
WO00004904A1 02/03/2000 PHARMACEUTICAL COMPOSITIONS COMPRISING HYDROXYLANSOPRAZOLE AND USES THEREOF
WO09967238A2 12/29/1999 DI- AND TETRA-HYDROQUINOLINE-INDOLE ANTIMICROBIAL AGENTS, USES AND COMPOSITIONS RELATED THERETO
WO09967198A1 12/29/1999 DESFORMOTEROL AND PROCESS FOR ITS PREPARATION
WO09967196A1 12/29/1999 FLUOXETINE PROCESS FROM BENZOYLPROPIONIC ACID
WO09965932A1 12/23/1999 TETRAPEPTIDES, ANALOGS AND PEPTIDOMIMETICS WHICH BIND SELECTIVELY MAMMALIAN OPIOID RECEPTORS
WO09965571A2 12/23/1999 USE OF OPTICALLY PURE (+)-NORCISAPRIDE FOR TREATING APNEA, BULIMIA AND OTHER DISORDERS
WO09965490A2 12/23/1999 USE OF OPTICALLY PURE (-) NORCISAPRIDE IN THE TREATMENT OF APNEA, BULIMIA, AND OTHER DISORDERS
WO09961014A2 12/02/1999 COMPOSITIONS AND METHODS EMPLOYING R(-) FLUOXETINE AND OTHER ACTIVE INGREDIENTS
WO09959590A1 11/25/1999 (+)-HYDROXYRISPERIDONE COMPOSITIONS AND METHODS
WO09959589A1 11/25/1999 (-)-HYDROXYRISPERIDONE COMPOSITIONS AND METHODS
WO09956748A1 11/11/1999 DESMETHYLPANTOPRAZOLE COMPOSITIONS AND METHODS
WO09956746A1 11/11/1999 HYDROXYOMEPRAZOLE COMPOSITIONS AND USES
WO09955158A1 11/04/1999 S-RABEPRAZOLE COMPOSITIONS AND METHODS
WO09955157A1 11/04/1999 R-RABEPRAZOLE COMPOSITIONS AND METHODS
WO09952555A1 10/21/1999 METHODS AND COMPOSITIONS USING NORASTEMIZOLE IN COMBINATION WITH LEUKOTRIENE INHIBITORS
One biggie here appears to be the Risperidone ICE - this is J&J's billion dollar antipsychotic. If the side effect profile of the ICE really is better, this could be very significant.
Another very interesting ICE is the metabolite of omeprazole (and also for the other PPI's). This is an alternative (end run?) to the chiral switch (Nexium) that AstraZeneca is about to pull, and should have the same advantages. As omeprazole is going off patent, this would potentially be exploitable immediately. Given the huge magnitude of the omeprazole market, this may well still have considerable value.
Vigabatrin is primarily an anti-epilepsy drug not available in the US. It is effective, but has a bad side-effect profile. The SEPR patent is for peripheral neuropathy (including Guillain-Barre) and for drug withdrawal, but not for epilepsy. A lot depends here on the magnitude of their side effect reduction and the absence of the epilepsy patent.
The broad dopamine reuptake patent is mainly for sibutramine in its various forms and combined with other agents(in particular serotonin-3 antagonists for e.g., ED).
Finally the intriguing nora/leukotrine inhibitor patent speaks to my previous hunch about Singulair - as I think I posted, MRK recently presented a Singulair/Claritin abstract.
Haven't had a chance to look at all these, but further evidence that the SEPR ICE gold rush is by no means over.
Peter |
